Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TYRA-430

Small molecule · Inhibitor of fibroblast growth factor receptor 3 (FGFR3) and fibroblast growth factor receptor 4 (FGFR4) · developed by Tyra Biosciences

Phase 1 Most advanced trial
TYRA Developer
1 Registered trials

What is TYRA-430?

TYRA-430 is an orally bioavailable, reversible inhibitor of fibroblast growth factor receptors 3 and 4 (FGFR3/4). It binds these receptors and blocks signaling mediated by the ligand FGF19, which is studied in tumors that overexpress FGF19 or FGFR4, including hepatocellular carcinoma and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
fibroblast growth factor receptor 3 (FGFR3), fibroblast growth factor receptor 4 (FGFR4)
Mechanism
Inhibitor of fibroblast growth factor receptor 3 (FGFR3) and fibroblast growth factor receptor 4 (FGFR4)
Pathways
FGF19-FGFR signaling, cell proliferation, cell survival, angiogenesis
Therapy area
Oncology
Developer
Tyra Biosciences, Inc (TYRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06915753 Phase 1 Metastatic Hepatocellular Carcinoma Recruiting TYRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsFGF19 Gene AmplificationFGF19 Gene OverexpressionFGFR Gene AlterationsFGFR Gene AmplificationFGFR4 Gene FusionsFGFR4 Gene MutationLocally Advanced Unresectable Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaSolid Tumor, AdultSolid Tumors

Other drugs acting on FGFR3 / FGFR4

More from Tyra Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.

Follow TYRA, the company behind TYRA-430

See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TYRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.